Dry EyeWINKNCT07499193
Study of Blinking as a Function of Tear Film Quality
A study testing Blink behaviour in people with Dry Eye, run by Essilor International at 1 site in France.
Trial summary
The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye. Read more about this study
- Who is it for?
- Ages 18 to 65 yearsHealthy volunteers can take part
- Conditions the study is for
- Dry Eye
- What is being tested?
- Blink behaviour
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteFrance
- Study dates
- Mar 2026to Jun 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information sheet and provide free and informed consent
- Covered by a social security
- Aged between 18 and 65 years inclusive
- Binocular near visual acuity ≤ 0.3 LogMAR (≥ 5/10) (corrective glasses accepted)
Who cannot join
- Employees of Essilor International, Luxottica, or GrandVision and their subsidiaries
- Pregnant or breastfeeding women (Article L1121-5)
- Individuals deprived of liberty by judicial or administrative decision, or hospitalized without consent under Articles L.3212-1 and L.3213-1, who do not fall under Article L.1121-8, and individuals admitted to a health or social care facility for purposes other than research
- Adults unable or incapable of giving informed consent (Article L1121-8)
- Participants currently in an exclusion period from another study
- Participants deemed unfit to participate by the investigator for any reason that may affect subject safety or study integrity All categories of individuals particularly protected under French law are excluded from this research (Articles L1121-5 to L1121-9 of the French Public Health Code).
Show all 13Show fewer
- Use of eye drops or ophthalmic solutions within the last 2 hours
- Wearing contact lenses within the last 48 hours
- Reported history of severe ocular pathology such as glaucoma, retinitis pigmentosa, diabetic retinopathy, macular involvement, resulting in visual field loss or acuity loss (especially aphakia), except for dry eye (which is not an exclusion criterion)
- Reported history of eye surgery or trauma to the eye or its adnexa excepted refractive surgery and cataract surgery
- Reported history of eyelid abnormalities (ptosis)
- Reported history of neurological deficits, including epilepsy or sensory-motor coordination disorders, vestibular or cerebellar pathology (e.g., balance disorders, nystagmus, Parkinson's disease)
- Reported history of musculoskeletal disorders preventing maintenance of a fixed head position
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
France1 site
EssilorLuxottica - Neuroscience & Medical Research center
Paris, 94220
Sarah Marié, MSc, +33177749169, mariesa@essilor.fr
About this study
Official title: Etude Des Clignements en Fonction de la Qualité du Film Lacrymal
The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye.
The main questions are:
Read more
- Do the results of a New Blink Task reflect tear film stability ?
- How are the blink related metrics in relation with each other? Researchers will compare two groups of participants-those without dry eye symptoms and those with dry eye symptoms-to see if blinking measures differ between them and whether these measures relate differently to tear film quality.
Participants will:
- Answer a questionnaire about dry eye symptoms
- Have their visual correction measured (if they wear glasses)
- Undergo non-invasive assessments of tear film quality using an imaging device
- Complete three types of blink tasks, each repeated three times, including measurements of blinking and of tear film stability
- Conditions
- Dry Eye
- Being tested
- Blink behaviour
- Keywords
- dry eye
- Medical subject headings
- Dry Eye Syndromes
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Blink behaviourOther
Single intervention
| Study group | Role | What they receive |
|---|---|---|
| Single arm | Experimental | Not described Receives: Other: Blink behaviour |
What is being measured
The primary outcome is the main question the study is designed to answer.
Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds and the non-invasive tear film break-up time measured in seconds measured with device IDRA .
Measured: Day one
Secondary outcomes (4)
Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds with parameters of dry eye ( tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %)) measured with device IDRA .
Measured: Day one
Compares the coefficient of variation of the Absolute Maximum Eye Aperture Duration (in %) with the coefficient of variation of the non-invasive tear film break-up time (in %) measured with device IDRA .
Measured: Day one
Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on two primary outcomes via linear regression model
Uses linear regression models to evaluate the effects of ocular surface characteristics (tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %) measured with device IDRA , demographics (age and gender), and task acceptability (questionnaire) on two primary outcomes:
Absolute Maximum Eye Aperture Duration (seconds) and the non-invasive tear film break-up time (seconds)
Measured: Day one
Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on coefficient of variation of two primary outcomes via linear regression model
Uses linear regression models to evaluate the effects of ocular surface characteristics (tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %) measured with device IDRA , demographics (age and gender), and task acceptability (questionnaire) on two primary outcomes:
Absolute Maximum Eye Aperture Duration (seconds) and the non-invasive tear film break-up time (seconds) on coefficient two primary outcomes: Absolute Maximum Eye Aperture Duration (%) and the non-invasive tear film break-up time (%)
Measured: Day one
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 Mar 2026
- Study startMar 2026 (estimated)
- Primary completionJun 2026 (estimated)
- Study completionJun 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Dry EyeStudies of the same condition, open and under way.
- More trials run by Essilor InternationalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Essilor International
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07499193
- Sponsor's protocol ID
- WS10489
- Other IDs
- 2025-A02676-43
- Acronym
- WINK
- Status last verified
- Mar 2026
- First submitted
- 17 Mar 2026
- Last updated
- 30 Mar 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 30 Mar 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Etude Des Clignements en Fonction de la Qualité du Film Lacrymal
- ClinicalTrials.gov ID
- NCT07499193
- Acronym / sponsor ID
- WINK / WS10489
- Conditions
- Dry Eye
- Keywords
- dry eye
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Essilor InternationalIndustry (pharma, biotech, devices)
- Study start
- Mar 2026 (estimated)
- Primary completion
- Jun 2026 (estimated)
- Study completion
- Jun 2026 (estimated)
- First posted
- 30 Mar 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this study is to better understand how eye blinking behavior is linked to the stability of the tear film, in adults aged 18 to 65 years, with or without symptoms of dry eye.
The main questions are:
- Do the results of a New Blink Task reflect tear film stability ?
- How are the blink related metrics in relation with each other? Researchers will compare two groups of participants-those without dry eye symptoms and those with dry eye symptoms-to see if blinking measures differ between them and whether these measures relate differently to tear film quality.
Participants will:
- Answer a questionnaire about dry eye symptoms
- Have their visual correction measured (if they wear glasses)
- Undergo non-invasive assessments of tear film quality using an imaging device
- Complete three types of blink tasks, each repeated three times, including measurements of blinking and of tear film stability
Study design
- Primary purpose
- Basic science
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Single arm | Experimental | Other: Blink behaviour |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Volunteer, fluent in French, willing to follow the protocol, able to read and understand the information sheet and provide free and informed consent
- Covered by a social security
- Aged between 18 and 65 years inclusive
- Binocular near visual acuity ≤ 0.3 LogMAR (≥ 5/10) (corrective glasses accepted)
Key exclusion criteria (13 listed)
- Employees of Essilor International, Luxottica, or GrandVision and their subsidiaries
- Pregnant or breastfeeding women (Article L1121-5)
- Individuals deprived of liberty by judicial or administrative decision, or hospitalized without consent under Articles L.3212-1 and L.3213-1, who do not fall under Article L.1121-8, and individuals admitted to a health or social care facility for purposes other than research
- Adults unable or incapable of giving informed consent (Article L1121-8)
- Participants currently in an exclusion period from another study
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Blink behaviourSingle intervention | Other | Single arm |
Primary outcome
Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds and the non-invasive tear film break-up time measured in seconds measured with device IDRA .
Time frame: Day one
4 secondary outcomes
Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds with parameters of dry eye ( tears meniscus height (mm), bulbar redness grade (from 0 to 4), blink quality (in %)) measured with device IDRA .
Time frame: Day one
Compares the coefficient of variation of the Absolute Maximum Eye Aperture Duration (in %) with the coefficient of variation of the non-invasive tear film break-up time (in %) measured with device IDRA .
Time frame: Day one
Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on two primary outcomes via linear regression model
Time frame: Day one
Evaluate the effects of ocular surface characteristics, demographics, and task acceptability on coefficient of variation of two primary outcomes via linear regression model
Time frame: Day one
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Mar 2026.
- Individual participant dataSharing planned: No
Related trials for Dry Eye
Not yet recruitingPhase 1
R-2487 in Patients With Sjogren's Syndrome (SjD)
Sjogren's Syndrome, Sjögren
RecruitingPhase 1
A Trial in Healthy Adult Participants and Adults With Autoimmune Diseases to Test How HBM7020 is Tolerated and How it Behaves in the Body
Rheumatoid Arthritis, Systemic Lupus Erythematosus
RecruitingObservational study
Pain Phenotyping of Rheumatic Diseases - An Observational Study
Rheumatic Diseases, Lupus Erythematosus, Systemic
RecruitingPhase 1/2
Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated With Age-Related Macular Degeneration
Dry Age-Related Macular Degeneration, Geographic Atrophy
RecruitingObservational study
The Pathogenesis and Natural History of Sjogren's Disease
Sjogren's Syndrome, Salivary Gland
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Blink behaviour in people with Dry Eye, run by Essilor International at 1 site in France.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 13 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 30 Mar 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Sarah Marié, MSc (+33177749169, mariesa@essilor.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Evaluates the correlation between the Absolute Maximum Eye Aperture Duration measured in seconds and the non-invasive tear film break-up time measured in seconds measured with device IDRA . (time frame: Day one). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Mar 2026.